Pankajakasthuri Herbal completes successful trial of ZingiVir-H

▴ zingivir-h-from-pankajakasthuri-herbal-completes-successful-trial
Pankajakasthuri Herbals is awaiting Ayush Ministry approval for Zingivir-H as add on therapy for COVID patients

Pankajakasthuri Herbals India announced significant success in their study to find a treatment for the novel coronavirus patients.

The company released the successful completion of the clinical trials for its tablet, ZingiVir-H as an add-on therapy for the pandemic. The clinical trials were conducted on 116 patients infected by COVID-19 at medical colleges across the country, with 58 being administered Zingivir-H and the rest were given a placebo. The studies found that 58 patients treated with the herbo-mineral drug, ZingiVir-H recovered and reported a negative Reverse Transcription Polymerase Chain Reaction (RT-PCR) recovery in an average of five days while others took an average of eight days to recover. The clinical trials of ZingiVir–H have been completed following the guidelines provided by the World Health Organization and the final results have been submitted to the Ministry of Ayurveda, Yoga & Naturopathy, Unani, Siddha and Homoeopathy (AYUSH) for approval.

Talking about the completion of the clinical trials, Dr J Hareendran Nair, Founder and MD of Pankaja Kasthuri Herbals and Pankajakasthuri Herbal Research Foundation said, “It gives me immense pride and honour to announce that our medication, ZingiVir–H, has been successful in providing much-needed assistance and help to COVID-19 patients in their recovery. This is one of the first herbo-mineral drug and ayurvedic medicine for COVID-19 that has achieved a negative RT PCR test as a primary endpoint.”

The clinical studies took place at KR Hospital, Mysuru, Karnataka; RCSM Medical College and CPR Hospital, Kolhapur, Maharashtra; Saveetha Medical College and Hospital, Chennai, Tamil Nadu and ESIC Medical College and Hospital, Faridabad, Haryana.

“We wanted to test the efficacy of the drug, which is made with seven ingredients, on patients in various hospitals across the country. This has further encouraged us and strengthened our belief that Ayurveda-based drugs can play a vital role in this fight against COVID-19. We are also soon planning to announce the results of the ongoing clinical trial with standalone treatment on 135 patients”, Dr Nair added.

Commenting on the Ministry of AYUSH to expedite the process of necessary approvals for all the Ayurveda drugs that are undergoing clinical trials in various hospitals in the country, Dr Nair said, “Today, when millions of people suffering from this harmful disease and are in hospitals battling the virus, I would like to urge the Ministry of AYUSH to support scientifically-backed modern Ayurveda-based treatments and drugs that have long-lasting benefits and can help save lives. At PKHIL, we are equipped to scale up and meet the requirements of the nation, once necessary approvals are issued by the ministry.”

Pankajakasthuri Herbals India submitted the first reports of ZingiVir-H to Ministry of AYUSH at the end of June 2020, while the interim report of 42 patients examined by a peer review committee was submitted on July 8 and the primary endpoint result of 116 patients was submitted to on July 24. The company is expecting the final decision from the ministry soon.

Tags : #Ayurveda #AyushMinistry #AyurvedicCureCovid #AdjunctTherapyCovid #AdjunctAyurvedicTherapyCovid #PankajakasthuriHerbals #CovidNewsUpdateAug7 #LatestCovidNewsAug7 #KRHospitalMysuru #SaveethaMedicalCollegeChennai #ESICMedicalCollegeFaridabad

About the Author

Team Medicircle

Related Stories

Loading Please wait...

Trending Now

'Teicoplanin' 10 times more effective in treating Covid-19 than HCQ: IIT Delhi researchOctober 01, 2020
Applied BioMath, LLC Announces Collaboration with Cullinan OncologyOctober 01, 2020
ViiV Healthcare to present long-term safety and efficacy data for 2-drug regimen October 01, 2020
Recovery rate of COVID patients in Delhi stands at 88.46 %October 01, 2020
HUYA Bioscience announces orphan drug Designation for HBI-8000 in JapanOctober 01, 2020
Jellagen Ltd announces a collaboration with the Mayo ClinicOctober 01, 2020
Lupin Launches Lapatinib TabletsSeptember 30, 2020
Ajinomoto Bio-Pharma Services and DNDi Partner to develop Critical Immunomodulator September 30, 2020
Lupin launches Lapatinib Tablets secures FDA approvalSeptember 30, 2020
Synthetic Biology introduces NanoSyrinxSeptember 30, 2020
Regular check-up & annual mammography are necessary to detect breast cancer earlySeptember 30, 2020
Regular use of acid influx drugs increase the risk of type-2 diabetesSeptember 30, 2020
Current pandemic introduces research culture in Ayush disciplineSeptember 30, 2020
Maharashtra govt calls for cancellation of Dandiya, Garba, other cultural programmes during ensuing Navratri, Durga PujaSeptember 30, 2020
Allotment of seats for admission in 1st year MBBS course will be done per existing policies: JIPMERSeptember 30, 2020
WHO to investigate allegations of sexual exploitation and abuse in Ebola response in the Democratic Republic of the CongoSeptember 30, 2020
South Korea puts virus curbs in place ahead of Chuseok holidaysSeptember 30, 2020
COVID-19 infection cases rising among U.S. childrenSeptember 30, 2020
India sustains steady trend of dipping %Active CasesSeptember 30, 2020
Private hospitals & diagnostic centres overcharging patients even for basic health services: Maharashtra Health MinisterSeptember 30, 2020